Galactosemia Market

 Market Overview:

The 7 major galactosemia markets reached a value of US$ 341.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 501.7 Million by 2034, exhibiting a growth rate (CAGR) of 3.57% during 2024-2034.

The galactosemia market has been comprehensively analyzed in IMARC's new report titled "Galactosemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Galactosemia refers to a rare genetic disorder that affects the body's ability to process galactose, a sugar found in milk and other dairy products. Some of the common symptoms of the ailment are failure to thrive, poor weight gain, jaundice, liver damage, vomiting, diarrhea, feeding difficulties in infants, etc. Cataracts, which can impair vision, are a characteristic feature of galactosemia and can occur in infancy or childhood. Various other potential indications include developmental delays, intellectual disabilities, speech difficulties, tremors, hypoglycemia, ovarian failure in females, etc. The condition is diagnosed through a combination of clinical evaluation, biochemical testing, and genetic analysis. Newborn screening programs play a crucial role in identifying infants with galactosemia shortly after birth by analyzing elevated levels of galactose or its metabolites in the blood. Confirmatory diagnostic testing involves further analysis of enzyme activity, such as measuring GALT or other relevant enzyme levels in red blood cells. Genetic testing can also be performed to identify specific gene mutations associated with galactosemia. Additionally, clinical evaluation and assessment of symptoms, along with family history, contribute to the diagnosis.

The increasing cases of inherited disorders, which lead to reduced or absent enzyme activity on account of gene variations, are primarily driving the galactosemia market. Besides this, the widespread adoption of prebiotics like galacto-oligosaccharides and probiotics for improving digestion and overall gastrointestinal health in patients is acting as another significant growth-inducing factor. Furthermore, the escalating usage of pharmacological chaperones, since they offer a convenient and non-invasive treatment option for individuals with galactosemia, is also bolstering the market growth. These agents bind to the defective enzyme, which is responsible for galactose metabolism, and help in preventing its degradation by increasing the stability. Additionally, several key players are making extensive investments in R&D activities to introduce compounds that inhibit galactose production and promote the removal of toxic metabolites. This, in turn, is further creating a positive outlook for the market. Moreover, the emerging popularity of mRNA therapies that boost the production of deficient enzymes and potentially restore the body's ability to metabolize galactose is expected to drive the galactosemia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the galactosemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for galactosemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the galactosemia market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the galactosemia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the galactosemia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current galactosemia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the galactosemia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the galactosemia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the galactosemia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of galactosemia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of galactosemia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of galactosemia by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with galactosemia across the seven major markets?
• What is the size of the galactosemia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of galactosemia?
• What will be the growth rate of patients across the seven major markets?
   

Galactosemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for galactosemia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the galactosemia market?
• What are the key regulatory events related to the galactosemia market?
• What is the structure of clinical trial landscape by status related to the galactosemia market?
• What is the structure of clinical trial landscape by phase related to the galactosemia market?
• What is the structure of clinical trial landscape by route of administration related to the galactosemia market?